Inspection Equipment

Abstract

To allow a user to execute a desired inspection using a plurality of measurement results on biological information in an inspection device.SOLUTION: A processor acquires a result of determination on whether or not first biological information is in an abnormal inclination, determined on the basis of a plurality of measurement results on first biological information on a user, acquires at least one inspection candidate for acquiring second biological information related to the first biological information, which is an inspection candidate to be recommended to the user, if the determination result is an abnormal inclination, presents the acquired inspection candidate to the user, receives the selection of the presented inspection candidate, and presents a guide according to the selected inspection candidate to the user.SELECTED DRAWING: Figure 6

Description

[Technical field]

[0001] The technology of the present disclosure relates to an inspection apparatus. [Background technology]

[0002] In recent years, wearable devices such as smart watches are becoming more commonplace for monitoring vital signs such as pulse, blood pressure, respiration, electrocardiograms, maximum oxygen intake, blood glucose equivalents, and body temperature, and for managing health promotion and disease prevention based on the vital signs. In addition, big data on vital signs is being used to train AI (Artificial Intelligence) to identify illnesses and potential illnesses with high accuracy.

[0003] Also, a method has been proposed for providing health management information to a user using biological information. For example, Patent Document 1 proposes a method for presenting a recommended action plan including exercise and meal contents when an abnormality is found in the blood glucose monitoring result acquired by a wearable device.

[0004] Meanwhile, an automated testing machine that automatically performs biological testing has been proposed, as described in Patent Document 2. The automated testing machine described in Patent Document 2 is provided with a removable test kit, and a user uses the test kit to collect a sample such as blood. When the user sets the sample in the automated testing machine, the automated testing machine performs a test using the sample and transmits the test results to the user's computer or mobile device. If such an automated testing machine is installed in a company, pharmacy, convenience store, or the like, the user can perform a test at a desired time without having to go to a hospital. [Prior art documents] [Patent documents]

[0005] [Patent Document 1] JP 2006-259827 A [Patent Document 2] JP 2012-068155 A Summary of the Invention [Problem to be solved by the invention]

[0006] Here, although wearable terminals can monitor biological information, the accuracy of the acquired biological information is lower than that of biological information based on blood tests, etc. In the method described in Patent Document 1, only a recommended action plan is presented to the user. Therefore, in the method described in Patent Document 1, when an abnormal tendency is observed in the monitoring results, the current state of the biological information cannot be grasped with high accuracy. In addition, in the method described in Patent Document 2, the user voluntarily performs a specific test using a test kit, and the test is not performed based on biological information acquired in a wearable terminal, etc.

[0007] The present disclosure has been made in consideration of the above circumstances, and has an object to enable a user to perform a desired test using the monitoring results of biological information. [Means for solving the problem]

[0008] The testing device according to the present disclosure includes at least one processor, which obtains a determination result of whether or not the first biometric information of a user is prone to abnormality, based on multiple measurement results of the first biometric information, and if the determination result indicates a tendency toward abnormality, obtains at least one test candidate recommended to the user for obtaining second biometric information associated with the first biometric information, presents the obtained test candidates to the user, accepts selection of the presented test candidates, and presents guidance to the user according to the selected test candidate.

[0009] Another testing device according to the present disclosure includes at least one processor, which obtains a determination result of whether or not the first biometric information is prone to abnormality, based on a monitoring result of the user's first biometric information, and if the determination result indicates a tendency toward abnormality, presents to the user at least one test candidate for obtaining second biometric information related to the first biometric information, and presents to the user guidance according to the test candidate selected by the user.

[0010] In the testing device according to the present disclosure, the processor may present test candidates for collecting a sample from a user to obtain second biometric information, and when the test candidate is selected, the processor may present instructions to the user for collecting the sample and obtain the second biometric information based on the sample collected by the user.

[0011] In the testing device according to the present disclosure, the processor may present the second biological information to a user.

[0012] The testing device according to the present disclosure may further include an analysis device that derives second biological information by analyzing the collected sample.

[0013] In a testing device according to the present disclosure, the processor may present test candidates in which a user's sample is delivered to an external testing institution to obtain second biometric information, and when the test candidate is selected, the processor may present the user with instructions for the procedure to deliver the user's first biometric information to the user.

[0014] A testing device according to the present disclosure may further include a storage case for storing a test kit necessary for conducting a test according to the presented candidate tests.

[0015] In the testing device according to the present disclosure, the test candidates may include test candidates from which the second biometric information can be obtained with higher accuracy than the first biometric information.

[0016] In the inspection device according to the present disclosure, the processor may accept specification of at least one item that serves as an indicator for a user to select from the presented test candidates, and present the test candidates in a display format corresponding to the specified item.

[0017] In the inspection device according to the present disclosure, the processor may present the user with questions to determine a display position of the test candidates on at least one scale corresponding to at least one specified item, determine the display position of the test candidates on the scale according to the answer to the question, and present the test candidates to the user in a display form in which an icon representing the test candidate is displayed at the determined display position on the scale.

[0018] In the inspection device according to the present disclosure, the processor may display an icon representing a candidate inspection item and then accept a user's designation of additional items, and when an item is added, the display format of the icon representing the candidate inspection item may be updated.

[0019] In the inspection device according to the present disclosure, the processor may repeatedly accept specifications for adding items, present questions corresponding to the added items, and update the display manner of the test candidates until a test candidate is selected by the user.

[0020] In the testing device according to the present disclosure, the items may include at least one of the cost of the test, the sense of security when collecting the sample, the degree of restraint during the test, whether the test is invasive or non-invasive, the time required to obtain test results, whether or not it includes risk checks for various diseases, and the accuracy of the test.

[0021] In the testing device according to the present disclosure, the processor may selectively determine a candidate test from among a plurality of testing methods that include designating a type of subject and for acquiring second biological information from the subject.

[0022] In the inspection device according to the present disclosure, the processor may determine the inspection candidates according to the degree of the abnormality tendency.

[0023] In the testing device according to the present disclosure, the processor may determine test candidates according to the amount of time that has elapsed since the first biological information was determined to have a tendency toward abnormality until the current time.

[0024] In the testing device according to the present disclosure, the processor may determine test candidates according to risk factors possessed by the user.

[0025] In the testing device according to the present disclosure, the processor may present, as guidance, support information to assist in the performance of the selected candidate test, the support information being transmitted in real time from a remote location.

[0026] The inspection device according to the present disclosure may be equipped with a camera that captures an image of a user, and the processor may transmit to a remote location video images obtained by capturing with the camera the user performing an inspection of a selected inspection candidate.

[0027] In the testing device according to the present disclosure, the processor may be configured to present statistical information of previously selected test candidates to a user.

[0028] In the testing device according to the present disclosure, the first biological information may be a blood glucose equivalent value correlated with a blood glucose level, and the second biological information may include at least one of a blood glucose level and HbA1c.

[0029] In the testing device according to the present disclosure, the abnormal tendency may be a postprandial hyperglycemic spike.

[0030] In the testing device according to the present disclosure, the processor may determine test candidates based on the user's dietary content.

[0031] In a testing device according to the present disclosure, the processor may determine test candidates based on the user's mealtimes.

[0032] In the testing device according to the present disclosure, the processor may present test candidates including the act of drinking a glucose drink if the time elapsed since a meal based on the meal time has passed a predetermined time.

[0033] In the testing device according to the present disclosure, the first biological information may be at least one of heart rate, blood pressure, respiration, electrocardiogram, maximum oxygen intake, arterial blood oxygen saturation and body temperature, and the second biological information may be a diagnosis result of the user's illness.

[0034] In the testing device according to the present disclosure, when a determination result indicating that the first biological information does not tend to be abnormal is obtained, the processor may give a notification to that effect.

[0035] In the inspection device according to the present disclosure, the processor may obtain the determination result via wireless communication.

[0036] In the testing device according to the present disclosure, the determination result may be derived by a measuring device worn by a user, and the processor may acquire the determination result from the measuring device.

[0037] In the testing device according to the present disclosure, the first biological information may be measured multiple times by a measuring device worn by a user, and the processor may acquire multiple measurement results of the first biological information from the measuring device, and based on the acquired multiple measurement results of the first biological information, determine whether the first biological information is prone to abnormality and acquire a determination result.

[0038] In this case, the meter may be wearable.

[0039] In the testing device according to the present disclosure, when it cannot be determined whether the first biological information shows a tendency toward abnormality, the processor may give a notification to increase the wearing time of the measuring device.

[0040] In the testing device according to the present disclosure, the processor may acquire second biological information, and determine whether or not to continue measuring the first biological information based on the acquired second biological information.

[0041] In the testing device according to the present disclosure, the processor may, after presenting to the user instructions corresponding to the selected test candidate, further present instructions corresponding to another test candidate that performs a test that is a step above the selected test candidate. Effect of the Invention

[0042] According to the present disclosure, a user can perform an examination based on the results of multiple measurements of biological information. [Brief description of the drawings]

[0043] [Figure 1] 1 is a schematic diagram showing a configuration of an inspection support system to which an inspection device according to an embodiment of the present disclosure is applied; [Diagram 2] 1 is a diagram showing a hardware configuration of an inspection device according to the present embodiment. [Diagram 3] Hardware configuration of a mobile device [Figure 4] Hardware configuration diagram of wristwatch-type measuring device [Diagram 5] Hardware configuration diagram of a meter for measuring glucose in interstitial fluid [Figure 6] 1 is a functional configuration diagram of an inspection device according to the present embodiment; [Figure 7] Diagram showing circadian blood glucose fluctuations in type 2 diabetes patients [Figure 8] Table showing the test methods for biological information related to blood glucose equivalent value [Figure 9] A flowchart showing the processing performed in this embodiment. [Figure 10] A flowchart showing the processing performed in this embodiment. [Figure 11] FIG. 13 is a diagram showing a notification screen when the blood glucose equivalent value is not showing an abnormal trend. [Figure 12] A diagram showing a screen presenting test candidates. [Figure 13] A diagram showing a screen presenting test candidates. [Figure 14] A diagram showing a screen presenting test candidates. [Figure 15] A diagram showing a screen presenting test candidates. [Figure 16] FIG. 13 shows a test candidate presentation screen with a description of the selected test candidate displayed. [Figure 17] FIG. 13 is a diagram showing a screen presenting test candidates on which statistical information of previously selected test candidates is displayed. [Figure 18] A diagram showing a list screen of items that serve as indicators for the user to select examination candidates. [Figure 19] A diagram showing a question display screen [Figure 20] FIG. 13 is a diagram showing a presentation screen that presents candidate tests to a user in a display format in which icons of candidate tests are displayed on a scale. [Figure 21] FIG. 13 is a diagram showing a presentation screen that presents candidate tests to a user in a display format in which icons of candidate tests are displayed on a scale. [Figure 22] A diagram showing a list screen of items that serve as indicators for the user to select examination candidates. [Figure 23] A diagram showing a question display screen [Figure 24] FIG. 13 is a diagram showing a presentation screen that presents candidate tests to a user in a display format in which icons of candidate tests are displayed on a scale when two items are selected. [Diagram 25] A diagram showing the information screen for booking an examination [Figure 26] A diagram showing the analysis results display screen [Figure 27] A diagram showing a guide screen for a website selling blood glucose measuring devices. [Figure 28] A diagram showing a guide screen that guides a user to hospitals where a glucose tolerance test can be performed. [Figure 29] A diagram showing the guidance screen for the next test [Diagram 30] FIG. 13 shows a notification screen for encouraging the user to increase the time the measurement device is worn. [Diagram 31]A diagram showing a comparison between the monitoring results of blood glucose equivalent values ​​and the test results obtained by a user taking a blood sample. [Diagram 32] A diagram showing the delivery procedure information screen [Diagram 33] Schematic diagram showing changes in heart rate variability, etc. in patients with COVID-19 [Diagram 34] Table showing testing methods related to COVID-19 [Diagram 35] FIG. 13 is a diagram showing a presentation screen that presents candidate tests to a user in a display format in which icons of candidate tests are displayed on a scale when two items are selected. [Diagram 36] FIG. 13 is a diagram showing a presentation screen that presents candidate tests to a user in a display format in which icons of candidate tests are displayed on a scale when two items are selected. [Figure 37] A diagram showing a question display screen DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0044] [First embodiment]

[0045] Hereinafter, a first embodiment of the present disclosure will be described with reference to the drawings. FIG. 1 is a schematic diagram showing a configuration of an inspection support system to which an inspection device according to a first embodiment of the present disclosure is applied. As shown in FIG. 1, an inspection support system 10 includes an inspection device 1 according to this embodiment, a mobile terminal 2 such as a smartphone, and measuring instruments 3 and 4. The mobile terminal 2 and the measuring instruments 3 and 4 are capable of communicating with each other by short-range wireless communication such as Bluetooth (registered trademark). The inspection device 1 and the measuring instruments 3 and 4 are also capable of communicating with each other by short-range wireless communication. The inspection device 1 and the mobile terminal 2 are also capable of communicating with each other by short-range wireless communication. The inspection device 1 is connected to an inspection server 6 via a wired or wireless network 5 in a communicable state.

[0046] The test device 1 is installed in places where people gather, such as convenience stores, shopping malls, stations, airports, companies, pharmacies, community centers, elderly care plazas, and hot spring facilities. Alternatively, the test device 1 is mounted on a mobile vehicle and moved to a desired location for use. The test device 1 determines whether the user's blood glucose equivalent value tends to be abnormal based on the monitoring result of the blood glucose equivalent value transmitted by the user from a measuring device 3 or the like as described below, and presents the user with test candidates for obtaining biological information related to the blood glucose equivalent value according to the determination result. In addition, the test device 1 presents the user with guidance according to the test candidates selected by the user, thereby assisting the user in the test performed by the user. Note that the blood glucose equivalent value is biological information that is correlated with the blood glucose value and is measured by a method that does not involve blood sampling. In addition, the test device 1 shown in FIG. 1 is shown with an analysis device 18 and a storage case 20, which will be described later.

[0047] The measuring device 3 is a wristwatch-type wearable terminal such as a smart watch, and has a function of monitoring a blood glucose equivalent value that is correlated with the user's blood glucose level. Monitoring means that the blood glucose equivalent value is automatically measured at predetermined time intervals, such as every 15 minutes or 30 minutes, without the user giving an instruction to measure. The measuring device 3 may be one that constantly measures the blood glucose equivalent value and also measures the blood glucose equivalent value when instructed by the user. The measuring device 3 may also be a type that is worn by the user only when measuring, such as a finger clip.

[0048] The measuring device 3 is a non-invasive measuring device for measuring blood glucose equivalent values, and for example, derives a blood glucose equivalent value by analyzing a signal emitted by glucose in the blood by irradiating the user with infrared rays. Alternatively, it measures the user's electrocardiogram and derives a blood glucose equivalent value that correlates with changes in the electrocardiogram. The measuring device 3 transmits the derived blood glucose equivalent value to the testing device 1.

[0049] The meter 4 is an invasive device for measuring a blood glucose equivalent value. For example, the meter 4 is worn by a user to monitor the glucose concentration in interstitial fluid under the user's epidermis and transmit the measured glucose concentration to the testing device 1. For this purpose, the meter 4 has a needle-shaped filament 4A that is inserted under the user's epidermis. The glucose concentration is correlated with the blood glucose level, and therefore serves as a blood glucose equivalent value.

[0050] The blood glucose equivalent value measured by the measuring devices 3 and 4 is an example of first biological information. It is necessary for a user to have only one of the measuring devices 3 and 4.

[0051] Here, in this embodiment, the testing device 1 judges whether the blood glucose equivalent value tends to be abnormal based on the monitoring result of the blood glucose equivalent value. In this embodiment, as the abnormal tendency of the blood glucose equivalent value, it judges whether or not there is a state of postprandial hyperglycemic spike. The postprandial hyperglycemic spike is a symptom seen in the early stage of diabetes, and is a symptom in which the blood glucose level rises significantly about 1 to 2 hours after a meal even if the fasting blood glucose level is within the normal range. If the postprandial hyperglycemic spike is left untreated, blood vessels are damaged, and arteriosclerosis and diabetes complications are likely to progress. It is also thought that complications such as myocardial infarction, angina pectoris, and stroke are likely to progress. In this embodiment, the blood glucose equivalent value is monitored, and when it is judged that the blood glucose equivalent value tends to be abnormal, a test candidate recommended for the user is presented to the user, so that the user is allowed to undergo a test that can obtain biological information for accurately grasping the postprandial hyperglycemic spike.

[0052] The network 5 is a wide area network (WAN: Wide Area Network) that connects the inspection devices 1 and the inspection server 6 over a wide area via a public line network or a dedicated line network.

[0053] The test server 6 is installed in a test center that supports tests related to blood glucose levels. The test server 6 has a function of providing the test program according to this embodiment to the test device 1, and providing information required for the test device 1 to execute the test program to the test device 1. The test server 6 is a general-purpose computer on which a software program that provides the functions of a server is installed.

[0054] The testing center provides various types of support to the user regarding blood glucose level testing. For example, the testing center provides support for the user to select a testing method by providing a testing program according to this embodiment. When the user selects a testing method, the testing center supports the purchase of equipment and testing kits required for the selected test, and supports the user in booking a test at a hospital. The testing center also performs testing using samples delivered by the user that the user has drawn themselves. The testing center is an example of an external testing institution.

[0055] Next, the inspection device according to the present embodiment will be described. First, referring to FIG. 2, the hardware configuration of the inspection device according to the present embodiment will be described. As shown in FIG. 2, the inspection device 1 according to the present embodiment includes a CPU (Central Processing Unit) 11, a non-volatile storage 13, and a memory 16 as a temporary storage area. The inspection device 1 also includes a touch panel 14, a communication I / F (InterFace) 15 for short-distance wireless communication, and a network I / F 17 wirelessly connected to a network 5. The inspection device 1 also includes an analysis device 18. The inspection device 1 also includes a housing case 20. The CPU 11, the storage 13, the touch panel 14, the communication I / F 15, the memory 16, the network I / F 17, and the analysis device 18 are connected to a bus 19. The CPU 11 is an example of a processor in the present disclosure.

[0056] The storage 13 is realized by an SSD (Solid State Drive), a flash memory, etc. The storage 13 as a storage medium stores the inspection program 12 installed in the inspection device 1. The CPU 11 reads out the inspection program 12 from the storage 13, loads it into the memory 16, and executes the loaded inspection program 12.

[0057] The touch panel 14 is made up of a liquid crystal display, an organic EL display, or the like, and displays various information related to the processing performed by the inspection device 1. The touch panel 14 also functions as an input device for performing various inputs to the inspection device 1.

[0058] The inspection program 12 is stored in the inspection server 6 in a state accessible from the outside, and is downloaded to and installed in the inspection device 1 upon request.

[0059] Analysis device 18 derives biological information such as blood glucose level, HbA1c (hemoglobin A1c) and the like by analyzing the user's blood. For this purpose, analysis device 18 has a mechanism for collecting the user's blood and a mechanism for acquiring blood from a test kit described later.

[0060] The storage case 20 contains a plurality of test kits 20A for calculating the blood of the user. The test kits 20A include a blood sampling instrument and a glucose drink for the user to drink before the test. When the user selects a test that involves self-sampling of blood as described below, the user can remove the test kit from the storage case, drink the glucose drink if necessary, and then use the blood sampling instrument to sample the user's own blood.

[0061] Next, the mobile terminal 2 will be described. Fig. 3 is a hardware configuration diagram of the mobile terminal 2. As shown in Fig. 3, the mobile terminal 2 is a mobile computer such as a smartphone, and includes a CPU 21, a non-volatile storage 23, and a memory 26 as a temporary storage area. The mobile terminal 2 also includes a touch panel 24, a communication I / F (InterFace) 25 that performs short-range wireless communication, and a network I / F 27 that is wirelessly connected to the network 5. The mobile terminal 2 also includes a camera 28. The CPU 21, the storage 23, the touch panel 24, the communication I / F 25, the memory 26, the network I / F 27, and the camera 28 are connected to a bus 29.

[0062] The storage 23 is realized by an SSD (Solid State Drive), a flash memory, etc. The analysis program 22 installed in the mobile terminal 2 is stored in the storage 23 as a storage medium. The CPU 21 reads out the analysis program 22 from the storage 23, expands it in the memory 26, and executes the expanded analysis program 22.

[0063] The touch panel 24 is made up of a liquid crystal display, an organic EL display, or the like, and displays various information related to the processes performed by the mobile terminal 2. The touch panel 24 also functions as an input device for performing various inputs to the mobile terminal 2.

[0064] The camera 28 photographs the user's meal, for example, in response to a user's instruction, thereby acquiring an image of the meal. The acquired image of the meal is stored in the storage 23. Alternatively, in response to a user's instruction or without waiting for an instruction, the image is transmitted to the testing device 1 together with the monitoring result of the blood glucose equivalent value, etc., as described below.

[0065] The analysis program 22 is stored in the testing server 6 in a state accessible from the outside, and is downloaded and installed in the mobile terminal 2 upon request. The analysis program 22 analyzes the monitoring results of the blood glucose equivalent values ​​transmitted from the measuring devices 3 and 4 to determine whether the blood glucose equivalent values ​​tend to be abnormal. The analysis program 22 may only execute a process of storing the blood glucose equivalent values ​​transmitted from the measuring devices 3 and 4 in the storage 23. When the monitoring results of the blood glucose equivalent values ​​are transmitted from the measuring devices 3 and 4 to the testing device 1, the mobile terminal 2 is not used.

[0066] In this embodiment, it is assumed that the user has completed user registration at the testing center. By authenticating the user at the testing device 1, the user is able to transmit the monitoring results of the blood glucose equivalent value to the testing device 1 and to perform testing at the testing device 1.

[0067] Next, the measuring device will be described. Fig. 4 describes the hardware configuration of measuring device 3. Measuring device 3 is a wristwatch-type computer, and as shown in Fig. 4, includes a CPU 31, non-volatile storage 33, and memory 36 as a temporary storage area. Measuring device 3 also includes a touch panel 34, a communication I / F 35 that performs short-range wireless communication, a network I / F 37 that is wirelessly connected to an external network (not shown), and a sensor 38. CPU 31, storage 33, touch panel 34, communication I / F 35, memory 36, network I / F 37, and sensor 38 are connected to a bus 39.

[0068] Storage 33 is realized by an SSD, a flash memory, etc. Storage 33 as a storage medium stores a measurement program 32 for measuring a blood glucose equivalent value installed in measuring device 3. CPU 31 reads out measurement program 32 from storage 33, expands it in memory 36, and executes the expanded measurement program 32.

[0069] Touch panel 34 is made up of a liquid crystal display, an organic EL display, or the like, and displays various information related to the processing performed by measurement instrument 3. Touch panel 34 also functions as an input device for performing various inputs to measurement instrument 3.

[0070] Sensor 38, which may be an infrared light source and an infrared detector, irradiates the user wearing measuring device 3 with infrared rays and detects a signal emitted by glucose in the blood. The signal detected by sensor 38 is analyzed by CPU 31 executing measurement program 32 to derive a blood glucose equivalent value. Sensor 38 may also measure an electrocardiogram. In this case, the measurement program 32 analyzes the electrocardiogram to derive a blood glucose equivalent value.

[0071] The measurement program 32 is stored in the inspection server 6 in a state accessible from the outside, and is downloaded and installed in the measuring instrument 3 upon request. Alternatively, the measurement program 32 is downloaded to the inspection device 1 or the mobile terminal 2, and then downloaded to the measuring instrument 3 via short-range wireless communication with the inspection device 1 or the mobile terminal 2 and installed.

[0072] In the measuring device 3, the sensor 38 detects a signal emitted by glucose in the blood at a predetermined time interval. The CPU 31 executes the measurement program 32 to analyze the signal and derive a blood glucose equivalent value. The CPU 31 then stores the derived blood glucose equivalent value in storage 33 in association with the measurement time. The blood glucose equivalent value associated with the measurement time becomes the monitoring result of the blood glucose equivalent value. When the user uses the testing device 1, the CPU 31 transmits the monitoring result of the blood glucose equivalent value from the communication I / F 35 to the testing device 1, either in response to a user instruction or without waiting for a user instruction.

[0073] Next, the measuring device 4 will be described. FIG. 5 is a hardware configuration diagram of the measuring device 4. As shown in FIG. 5, the measuring device 4 is a measuring device that is attached to the human body and measures the glucose concentration in the interstitial fluid under the epidermis as a blood glucose equivalent value, as described in, for example, JP2016-520379A. The measuring device 4 includes a processor 41, a memory 42 as a temporary storage area, a communication I / F 43 that performs short-range wireless communication, and a sensor 44. A needle-shaped filament 4A that is inserted under the epidermis is connected to the sensor 44. The processor 41, the memory 42, the communication I / F 43, and the sensor 44 are composed of an integrated circuit (ASIC (Application Specific Integrated Circuit)) 45 for measuring glucose in the interstitial fluid.

[0074] In the measuring device 4, the sensor 44 detects a signal representing the glucose concentration in the interstitial fluid under the epidermis at a predetermined time interval or in response to a measurement instruction from the user. The processor 41 analyzes the signal to derive the glucose concentration. The processor 41 further stores the derived glucose concentration in the memory 42 in association with the measurement time. The blood glucose equivalent value associated with the measurement time becomes the monitoring result of the blood glucose equivalent value. Then, when the user uses the testing device 1, the processor 41 transmits the monitoring result of the blood glucose equivalent value from the communication I / F 43 to the testing device 1, either in response to a user instruction or without waiting for a user instruction.

[0075] Next, the functional configuration of the testing device according to this embodiment will be described. Fig. 6 is a diagram showing the functional configuration of the testing device according to this embodiment. As shown in Fig. 6, the testing device 1 includes an acquisition unit 51, a judgment unit 52, a decision unit 53, and a presentation unit 54. The CPU 11 executes the testing program 12 to function as the acquisition unit 51, the judgment unit 52, the decision unit 53, and the presentation unit 54. In the following description, it is assumed that the user has a measuring device 3, and the testing device 1 directly acquires the monitoring results of the blood glucose equivalent value from the measuring device 3.

[0076] The acquisition unit 51 acquires the monitoring results of the blood glucose equivalent value transmitted from the communication I / F 35 of the measuring device 3 by receiving the same via the communication I / F 15. In this embodiment, for example, the monitoring results of the blood glucose equivalent value measured in the most recent 24 hours are acquired.

[0077] The determination unit 52 determines whether or not the blood glucose equivalent value tends to be abnormal based on the monitoring result of the blood glucose equivalent value acquired by the acquisition unit 51. Specifically, the determination unit 52 determines whether or not the blood glucose equivalent value tends to be a postprandial hyperglycemic spike.

[0078] Here, postprandial hyperglycemia will be explained. FIG. 7 is a diagram showing the diurnal blood glucose fluctuation of a type 2 diabetes patient. In FIG. 7, the horizontal axis is the time of day (24 hours), and the vertical axis is blood glucose level (mg / dL). The solid line shows the blood glucose level of a patient with HbA1c (hemoglobin A1c) of 9% or more. The dashed line shows the blood glucose level of a patient with HbA1c of 7 to less than 8%. The dashed line shows the blood glucose level of a patient with HbA1c of 6.5% to less than 7%. FIG. 7 also shows the blood glucose level fluctuation when breakfast is eaten around 8:00, lunch around 12:00, and dinner around 19:00. HbA1c is a component of red blood cells in blood that is formed by binding glucose to hemoglobin. HbA1c represents the blood glucose fluctuation over one to two months.

[0079] As shown in Figure 7, regardless of the HbA1c value, blood glucose levels rise after meals, but the higher the HbA1c, the more pronounced the postprandial hyperglycemic spike, in which blood glucose levels rise significantly, especially after breakfast. To make the postprandial hyperglycemic spike after breakfast easier to see, a line has been added at the 8 o'clock position in Figure 7.

[0080] Furthermore, the user transmits the most recent meal time from the measuring device 3 to the inspection device 1. Alternatively, the meal time may be input from the touch panel 14 of the inspection device 1. Alternatively, the meal may be photographed by the camera 28 of the mobile terminal 2, and the photographed image of the meal may be transmitted to the inspection device 1. In this case, the information on the photographing date and time included in the header information of the photographed image of the meal can be used as the meal time.

[0081] The determination unit 52 determines that the blood glucose equivalent value is tending to be abnormal when the blood glucose equivalent value changes over time after a meal to a predetermined threshold value Th1 or more in the monitoring result of the blood glucose equivalent value transmitted from the measuring device 3. In this embodiment, the change over time is, for example, the change in blood glucose level per hour.

[0082] In this embodiment, the judgment unit 52 further judges whether or not there was a situation in which the fluctuation of the blood glucose equivalent value was equal to or greater than the threshold value Th2, and if the judgment is affirmative, the judgment unit 52 judges that the postprandial hyperglycemic spike is large. Note that Th2>Th1. If the judgment is negative, the judgment unit 52 judges that the postprandial hyperglycemic spike is small.

[0083] When the determining unit 52 determines that the blood glucose equivalent value is not showing an abnormal tendency, it notifies the user of the result. The notification will be described later.

[0084] The determination unit 53 determines candidate tests to be recommended to the user when the determination unit 52 determines that the blood glucose equivalent value tends to be abnormal. Furthermore, the determination unit 53 determines the candidate tests depending on the degree of the tendency to abnormality.

[0085] Fig. 8 is a table showing test methods for biological information related to blood glucose equivalent values. In Fig. 8, the test method, biological information to be measured, cost, and required time are shown as test information for four types of test methods (1) to (4). All of the test methods (1) to (4) are test methods in which blood is drawn from the user.

[0086] Test method (1) is a test method that measures only blood glucose level. Test method (2) is a test method that performs several tests in addition to blood glucose level. In FIG. 8, several test methods are indicated with "+α". Test method (3) is a test method that tests blood glucose level, HbA1c, and multiple other items. Test method (4) is a test method that measures HbA1c only. In FIG. 8, multiple items other than blood glucose level and HbA1c are indicated with "+other multiple items". Note that test methods (1), (2), and (4) can be performed by the analysis device 18 of the testing device 1, and in that case, the test results can be obtained in a relatively short time. The obtained test results are displayed on the touch panel 14. Test method (3) is a test performed by delivering a sample to a testing center, which is an external testing institution.

[0087] The blood glucose level, HbA1c and other biological information obtained by the test methods (1) to (4) are examples of second biological information.

[0088] Fig. 8 also shows various items that serve as indicators for the user when selecting a presented test candidate. Specifically, the items shown are the cost required for the test (cost), the time required to obtain the test results (time required), whether or not risk checks for various diseases are included (risk check), and the accuracy of the test (accuracy). The column for each item shows the degree of desirability for each test method. The degrees of desirability are represented by the symbols A, B, C, and D in order of desirability. A stands for very preferred, B for preferred, C for neutral, and D for unpreferred.

[0089] With regard to cost, the cheaper it is, the more preferable it is. With regard to time required, the shorter it is, the more preferable it is. With regard to risk checks for various diseases, the more test items there are and the more tests for diseases other than diabetes are included, the more preferable it is. With regard to accuracy, the higher the accuracy in detecting postprandial hyperglycemia, in particular, the more preferable it is.

[0090] In addition to the cost, time required, risk check, and accuracy, the items may include the sense of security when collecting the specimen, the degree of constraint during the test, and whether the test is invasive or non-invasive. The sense of security increases as the user feels less anxious about collecting the specimen (e.g., blood collection). For example, if the test method involves blood collection at a hospital, blood collection by a medical professional gives the user a high sense of security. The degree of constraint varies depending on whether the user has to go out and the waiting time, and increases the degree of preference when the user does not have to go out and the waiting time is short. The degree of preference for invasiveness increases when the specimen can be obtained without pain. For example, if the test method involves a glucose tolerance test, the degree of preference for invasiveness decreases because blood needs to be collected three times after glucose loading.

[0091] In addition, various abnormal trends in blood glucose equivalent values ​​are shown in Figure 8. Specifically, it is shown that the postprandial hyperglycemic spike is large and the postprandial hyperglycemic spike is small.

[0092] In addition, in FIG. 8, for each abnormal tendency, a circle is marked in the column for the test method that should be a test candidate. That is, when the postprandial hyperglycemic spike is large, a circle is marked for test methods (1) to (3). Note that for test methods (1) to (3), postprandial blood sampling is essential to determine the postprandial hyperglycemic spike. When the postprandial hyperglycemic spike is small, a circle is marked for all test methods (1) to (4).

[0093] In this embodiment, the table shown in FIG. 8 is stored as a table in the storage 13. The determination unit 53 refers to the table stored in the storage 13 and determines the test candidates according to the abnormal tendency of the blood glucose equivalent value determined by the determination unit 52. Specifically, when the abnormal tendency determined by the determination unit 52 is a large postprandial hyperglycemia spike, the determination unit 53 refers to the table and determines the test methods (1) to (3) as the test candidates. When the abnormal tendency determined by the determination unit 52 is a small postprandial hyperglycemia spike, the determination unit 53 determines the test methods (1) to (4) as the test candidates. Note that all of the test methods (1) to (4) can be used to collect blood using the testing device 1, and the collected blood sample can be delivered to a testing center for testing. On the other hand, the test method (3) requires that the sample be delivered to a testing center, which is an external testing institution, for testing.

[0094] The presentation unit 54 presents to the user the test candidates determined by the determination unit 53. In the present embodiment, the presentation unit 54 presents to the user the test candidates determined by the determination unit 53 by displaying the test candidates determined by the determination unit 53 on the touch panel 14.

[0095] The process performed in this embodiment will be described below. FIG. 9 and FIG. 10 are flow charts showing the process performed in this embodiment. In order to determine whether the blood glucose equivalent value has an abnormal tendency, the acquisition unit 51 monitors whether the communication I / F 15 has received the monitoring result of the blood glucose equivalent value transmitted from the measuring device 3 (step ST1). If step ST1 is positive, the judgment unit 52 judges whether the blood glucose equivalent value has an abnormal tendency based on the monitoring result of the blood glucose equivalent value (step ST2). If step ST2 is negative, the judgment unit 52 notifies the user that the blood glucose equivalent value is not abnormal (step ST3) and returns to step ST1. FIG. 11 is a diagram showing a notification screen when the blood glucose equivalent value is not abnormal. As shown in FIG. 11, a notification 61 of "The blood glucose equivalent value is not abnormal. Please continue your current lifestyle habits" is displayed on the notification screen 60.

[0096] If step ST2 is positive, the judgment unit 52 judges the degree of the abnormal tendency of the blood glucose equivalent value. First, the judgment unit 52 judges whether or not there was a situation in which the fluctuation of the blood glucose equivalent value was equal to or greater than the threshold value Th2, based on the monitoring result of the blood glucose equivalent value (step ST4). If step ST4 is positive, the decision unit 53 decides, as a test candidate, a test method for a large postprandial hyperglycemic spike, among the test methods included in the table shown in FIG. 8 (step ST5). If step ST4 is negative, the decision unit 53 decides, as a test candidate, a test method for a small postprandial hyperglycemic spike, among the test methods included in the table shown in FIG. 8 (step ST6).

[0097] Following steps ST5 and ST6, the determination unit 52 determines whether the current time is within two hours after a meal based on the meal time (step ST7). If step ST7 is positive, the presentation unit 54 does not add drinking a glucose drink to the test candidates (no drink added; step ST8) and presents the determined test candidates to the user (step ST10). On the other hand, if step ST7 is negative, the presentation unit 54 adds drinking a glucose drink to the test candidates (add drink; step ST9) and presents the determined test candidates to the user (step ST10).

[0098] FIG. 12 is a diagram showing a screen for presenting test candidates. As shown in FIG. 12, a screen 62 for presenting test candidates displays test candidates 63 for cases of large postprandial hyperglycemic spikes and including a drink. That is, for each of the test method (1) "blood glucose level only," the test method (2) "blood glucose level + α," and the test method (3) "blood glucose level + HbA1c + other items," a total of six test candidates are displayed for tests with a drink and tests for which a blood collection container will be delivered later. For tests with a drink, "drink &" is displayed, and for tests for which a blood collection container will be delivered later, "blood collection container delivery &" is displayed. The presentation screen 62 also includes a statistical information reference button 64, an item selection button 65, and a decision button 66. The statistical information reference button 64 is for displaying statistical information as described later. The item selection button 65 is for displaying a list screen of items that serve as an index when the user selects a test candidate as described later. The decision button 66 is for deciding the test candidate.

[0099] A screen 62A showing test candidates when the postprandial hyperglycemia spike is large and does not include a drink is shown in FIG. 13. A screen 62B showing test candidates when the postprandial hyperglycemia spike is small and does not include a drink is shown in FIG. 14. A screen 62C showing test candidates when the postprandial hyperglycemia spike is small and does not include a drink is shown in FIG. 15. The screen 62A shown in FIG. 13 displays a test candidate 63A when the postprandial hyperglycemia spike is large and does not include a drink. The screen 62B shown in FIG. 14 displays a test candidate 63B when the postprandial hyperglycemia spike is small and does not include a drink. The screen 62C shown in FIG. 15 displays a test candidate 63C when the postprandial hyperglycemia spike is small and does not include a drink. In addition, when the postprandial hyperglycemic spike is small, the test candidates selected are test method (1) "blood glucose level only", test method (2) "blood glucose level + α", test method (3) "blood glucose level + HbA1c + other items", and test method (4) "HbA1c only". In the following explanation, it is assumed that the display screen 62 shown in FIG. 12 is displayed.

[0100] Each test candidate included in the test candidates 63 is selectable, and when the user selects a test candidate included in the test candidates, an explanation of the selected test candidate is displayed. For example, when the user selects "Drink & Blood Glucose Only" from the six test candidates, an explanation 67 saying "This is a test in which blood is drawn 60 minutes after drinking a glucose drink" is displayed between the item selection button 65 and the decision button 66, as shown in FIG. 16. When the user selects the decision button 66 in this state, the selected test candidate is decided as the test method to be performed by the user. The process after the test method is decided will be described later.

[0101] Also, when the user selects the statistical information reference button 64, statistical information of previously selected test candidates is displayed. Here, multiple test candidates are selected according to the abnormal tendency of the user's blood glucose equivalent value and presented to the user, and the user selects one of the multiple test candidates to perform the test. The statistical information indicates the proportion of multiple test candidates selected in the past by the user currently performing the test or by other users. The statistical information is derived by tallying up which test candidates were selected in the past for test candidates with the same abnormal tendency as the user's blood glucose equivalent value. For example, if the abnormal tendency of the user's blood glucose equivalent value is large postprandial hyperglycemic spike, statistical information about the six presented test candidates is displayed.

[0102] Fig. 17 is a diagram showing a screen for presenting test candidates on which statistical information of the test candidates is displayed. As shown in Fig. 17, statistical information 68 for each of the six presented test candidates is displayed between an item selection button 65 and a decision button 66. As shown in Fig. 17, the statistical information 68 indicates the proportion of times each test candidate has been selected in the past as a percentage. The statistical information 68 is stored in the test server 6, and when the statistical information reference button 64 is selected, the mobile terminal 2 accesses the test server 6 to obtain the statistical information 68 and presents it to the user.

[0103] Even when statistical information 68 is displayed, if the user selects any one of the candidate examinations and selects decision button 66, the selected candidate examination is decided as the examination method to be performed by the user.

[0104] After presenting the test candidates, the determination unit 53 judges whether or not the decision button 66 has been selected (step ST11), and if step ST11 is positive, the process proceeds to step ST19, which will be described later. If step ST11 is negative, the determination unit 53 judges whether or not the item selection button 65 has been selected (item selection; step ST12). If step ST12 is negative, the process returns to step ST10. If step ST12 is positive, the presentation unit 54 displays a list of items (step ST13).

[0105] FIG. 18 is a diagram showing a list screen displaying a list of items. As shown in FIG. 18, the item list screen 70 displays the text "Which item do you want to prioritize?". In addition, the list screen 70 displays the cost required for the test, the time required to obtain the test results, the risk check for various diseases, and the accuracy of the test as items that serve as indicators when selecting a test candidate. In addition, a check box 71 is attached to each item. The user specifies an item by checking the check box of any item that the user wants to prioritize when selecting test information, and selects the item specification button 72. For this purpose, the determination unit 53 determines whether the item specification button 72 has been selected (step ST14). If step ST14 is negative, the process returns to step ST13. If step ST14 is positive, the determination unit 53 presents the user with a question for determining the display position of the test candidate on a scale described later according to the specified item (step ST15).

[0106] FIG. 19 is a diagram showing a question presentation screen. For the sake of explanation, it is assumed here that the user has selected "time required to obtain test results" as an item that serves as an index for selecting a test candidate. As shown in FIG. 19, two questions Q1 and Q2 are displayed on question presentation screen 75. Question Q1 is "If you are going to drink a drink, will you drink it now?" and question Q2 is "If blood is to be collected at home, when will the blood collection container be delivered?". The user answers question Q1 with YES or NO. For question Q2, the user inputs the date and time when the blood collection container will be delivered in input box 76. It is assumed here that the user has answered question Q1 with YES and input tomorrow's date for question Q2.

[0107] When the user selects the answer end button 77 after answering, the determination unit 53 determines the position on the scale corresponding to the specified item to display the test candidates. Then, the presentation unit 54 presents the test candidates to the user in a display form in which an icon representing the test candidate is displayed at the determined display position on the scale (presentation of test candidate scale; step ST16). Here, in this embodiment, "time required until test result is obtained" is selected as an item that serves as an index for selecting the test candidates. Therefore, the determination unit 53 derives the time required until test result is obtained according to the answer to the question, and determines the display position of the test candidate on the scale representing the required time. Then, the presentation unit 54 presents the test candidates to the user in a display form in which an icon of the test candidate is displayed at the determined display position on the scale.

[0108] FIG. 20 is a diagram showing a presentation screen that presents candidate test items to a user in a display form in which icons of candidate test items are displayed on a scale. As shown in FIG. 20, a scale 79 showing the required time is displayed on the presentation screen 78, and six candidate test items 80A to 80F are arranged along the scale 79 according to the required time. As shown in FIG. 20, the display position on the scale 79 of the candidate test item 80A corresponding to "drink & blood glucose level only" is "65 minutes later." This is because the answer to question Q1 is to drink a drink now, blood is drawn 60 minutes later, and the result is available 5 minutes after the start of the test. In addition, the display position on the scale 79 of the candidate test item 80B corresponding to "drink & blood glucose level + α" is "75 minutes later." This is because the answer to question Q1 is to drink a drink now, blood is drawn 60 minutes later, and the result is available 15 minutes after the start of the test. In addition, the display position on the scale 79 of the candidate test item 80C corresponding to "drink & blood glucose level + HbA1c + many other items" is "3 days later." This is because, although the patient responded to question Q1 that they would drink the drink now, it will take three days for all test results to become available.

[0109] The display position on the scale 79 of the candidate test icon 80D corresponding to "Blood collection container delivery & blood glucose level only" and the candidate test icon 80E corresponding to "Blood collection container delivery & blood glucose level + α" is "tomorrow." This is because the answer to question Q2 is that the blood collection container will be delivered tomorrow. The display position on the scale 79 of the candidate test icon 80F corresponding to "Blood collection container delivery & blood glucose level + HbA1c + many other items" is "4 days later." This is because the answer to question Q2 is that the blood collection container will be delivered tomorrow, and it will take another 3 days for all the test results to be available.

[0110] In addition, if the user is in a situation within 2 hours after a meal, the display screen 62A shown in FIG. 13 is displayed, and a question is asked as to whether blood should be taken immediately, and the user answers YES to the question. In addition, the display screen of the test candidates in FIG. 21 shows a display screen of the test candidates in the case where the user answers YES to the question. In addition, the display screen 62A shown in FIG. 13 does not show that there is no drink, but the icon shown in FIG. 21 shows that there is no drink. In the display screen 78A shown in FIG. 21, the display position on the scale 79 of the icon 80G of the test candidate corresponding to "no drink & blood glucose level only" is "5 minutes later". This is because the result is available 5 minutes after the start of the test. In addition, the display position on the scale 79 of the icon 80H of the test candidate corresponding to "no drink & blood glucose level + α" is "15 minutes later". This is because the result is available 15 minutes after the start of the test. In addition, the display position on the scale 79 of the icon 80I of the test candidate corresponding to "no drink & blood glucose level + HbA1c + many other items" is "3 days later". This is because it takes three days for all test results to become available.

[0111] The user can instantly recognize the required dates and times for the presented candidate examinations on the presentation screen 78. This allows the user to easily compare the candidate examinations according to the items that the user considers important.

[0112] The user can select an icon of a candidate test on the presentation screen 78 and select the decision button 81 to decide the test method desired by the user. In addition, by selecting the item selection button 82, an item that serves as an index for selecting a candidate test can be additionally specified. For this purpose, following step ST16, the decision unit 53 judges whether or not the item selection button 82 has been selected (step ST17). If step ST17 is positive, the process returns to step ST13, and the processes of steps ST13 to ST17 are repeated. If step ST17 is negative, the decision unit 53 judges whether or not the decision button 81 has been selected (step ST18). If step ST18 is positive, the process proceeds to step ST19, which will be described later. If step ST18 is negative, the process returns to step ST16.

[0113] FIG. 22 is a diagram showing the item list screen that is displayed for the second time when step ST17 is determined to be positive. As shown in FIG. 22, among the check boxes 71 displayed on the item list screen 70, the check box for "time required to obtain test results" is already checked. The user can select further items on the item list screen 70. Here, it is assumed that the user further selects "cost required for test." The determination unit 53 presents the user with a question for determining the display position of the candidate test on the scale according to the "cost required for test."

[0114] FIG. 23 is a diagram showing a question presentation screen regarding "cost required for examination." As shown in FIG. 23, one question Q3 is presented on the question presentation screen 84. The question Q3 is "Would you like to order a drink?" The user answers the question with YES or NO. Here, it is assumed that the user answers with YES. After answering, when the user selects the answer end button 85, the presentation unit 54 updates the display form of the icon representing the examination candidate. That is, the determination unit 53 determines the display position of the examination candidate on the additional scale according to the additionally specified item, and the presentation unit 54 presents the examination candidate to the user in a display form in which the icon representing the examination candidate is displayed at the determined display position on the already presented scale and the additional scale.

[0115] Specifically, the determination unit 53 derives the cost of the test based on the answer to the question, and determines the display position of the candidate test on a scale representing the cost of the test. The presentation unit 54 then displays the scale of the required time and the scale of the cost of the test so as to be perpendicular to each other, and presents the candidate test to the user by displaying icons of the candidate test at positions on the two perpendicular scales.

[0116] FIG. 24 is a diagram showing a presentation screen that presents candidate tests to a user in a display form in which icons of candidate tests are displayed on a scale when two items are selected. As shown in FIG. 24, a scale 87 representing costs is displayed perpendicularly to a scale 79 representing the required time on a presentation screen 86, and six candidate test icons 80A to 80F are displayed in a two-dimensional arrangement according to the required time and costs. As shown in FIG. 24, the display position on the scale 79 of the candidate test icon 80A corresponding to "drink & blood glucose only" is "65 minutes later," and the display position on the scale 87 is 600 yen. The cost is the cost of the blood glucose only test plus the cost of the glucose drink.

[0117] Additionally, the display position on scale 79 of icon 80B, which is a candidate for the test, corresponding to "drink & blood glucose level + α" is "75 minutes later," and the display position on scale 87 is 2,300 yen. The cost is the cost of the blood glucose level + α test plus the cost of the glucose drink. Additionally, the display position on scale 79 of icon 80C, which is a candidate for the test, corresponding to "drink & blood glucose level + HbA1c + many other items," is "3 days later," and the display position on scale 87 is 4,300 yen. The cost is the cost of the blood glucose level + HbA1c + many other items test plus the cost of the glucose drink.

[0118] In addition, the display position on the scale 79 of the icon 80D of the candidate test corresponding to "Blood collection container delivery & blood glucose level only" and the display position on the scale 87 of the icon 80E of the candidate test corresponding to "Blood collection container delivery & blood glucose level + α" is "tomorrow", and the display position on the scale 87 is slightly higher than the icons 80A and 80B. This is because the cost of "Drink & blood glucose level only" and "Drink & blood glucose level + α" includes the transportation cost (e.g., 300 yen) when the blood collection container is delivered again to the testing device 1. In addition, the display position on the scale 79 of the icon 80F of the candidate test corresponding to "Blood collection container delivery & blood glucose level + HbA1c + other items" is "4 days later", and the display position on the scale 87 is slightly higher than the icon 80C. This is because the cost of "Drink & blood glucose level + HbA1c + other items" and "Drink & blood glucose level + α" includes the transportation cost when the blood collection container is delivered again to the testing device 1.

[0119] The user can instantly recognize the required dates and times and costs for the proposed examinations presented on the presentation screen 86. This makes it easy to compare the proposed examinations taking into account both the required dates and times and costs.

[0120] On the presentation screen 86, the user can select the icon of a candidate test and select the decision button 81 to determine the test method desired by the user. In addition, by further selecting the item selection button 82, the user can specify additional items that will be used as indicators when selecting the candidate test. This makes it possible to add additional items and compare the candidate tests until the user is satisfied.

[0121] If step ST11 and step ST18 are positive, the presentation unit 54 displays on the touch panel 14 a guide for the test method selected by the user (step ST19). For example, if the user selects "drink & blood glucose only" on the presentation screen 62, etc., blood sampling is required 60 minutes later, so the presentation unit 54 displays a guide screen for reserving a test. FIG. 25 is a diagram showing a guide screen for reserving a test. On the reservation guide screen 89 shown in FIG. 25, the user inputs the desired reservation time in an input box 90. After that, when the reservation button 91 is selected, the reservation is completed. The testing device 1 is controlled so as not to obtain monitoring results of blood glucose equivalent values ​​of other users and not to perform testing from several minutes before the time when the user made the reservation.

[0122] Following step ST19, the decision unit 53 stores the acquired monitoring results of the user's blood glucose equivalent value in the storage 13 in association with the acquisition date and time and the abnormal tendency (step ST20). Furthermore, the decision unit 53 associates the acquired monitoring results of the user's blood glucose equivalent value with the acquisition date and time, the abnormal tendency, and the selected test candidate, processes the results so that the user cannot be identified, and transmits them to the test server 6 (step ST21), and ends the process. Note that if an image of the meal is acquired, the image is also transmitted to the test server 6. The acquired information is accumulated in the test server 6.

[0123] The user goes to the location where the testing device 1 is installed at the scheduled time and either draws blood in the analysis device 18, or loads a blood collection container containing blood drawn using a test kit into the analysis device 18. The analysis device 18 then analyzes the blood according to the test method selected by the user and derives the analysis results. The analysis results are displayed on the touch panel 14. Figure 26 is a diagram showing the display screen of the analysis results. As shown in Figure 26, the analysis result display screen 92 displays, as an example, the blood glucose analysis result of "150 mg / dL".

[0124] In this manner, in this embodiment, when the monitoring result of the user's blood glucose equivalent value shows an abnormal tendency, candidate tests for acquiring biological information related to the blood glucose equivalent value are presented to the user, and guidance according to the candidate test selected by the user is presented to the user. Therefore, the user can use the testing device according to this embodiment to perform a test according to the monitoring result of the blood glucose equivalent value. In addition, the user will not perform a test that is not in line with the abnormal tendency of his or her own blood glucose level. Therefore, personalized medical care that is tailored to the user can be promoted.

[0125] Furthermore, by presenting test candidates that can obtain biological information related to blood glucose equivalent values ​​with higher accuracy than the measuring devices 3 and 4, the user can select a test that will allow them to accurately understand their own blood glucose status. Therefore, by taking the selected test, the user can more accurately understand their own blood glucose status.

[0126] In addition, by accepting the designation of at least one item that serves as an index when the user selects the candidate tests and presenting the candidate tests in a display format according to the designated item, the candidate tests can be presented in a display format that reflects the items that the user wants to emphasize when selecting the candidate tests, thereby enabling the user to easily select the candidate tests.

[0127] Furthermore, by presenting the user with questions to determine the display positions of the candidate tests on a scale according to the specified items, determining the display positions of the candidate tests on the scale according to the answers to the questions, and presenting the candidate tests to the user in a display form that displays icons representing the candidate tests at the determined display positions on the scale, the candidate tests can be presented to the user in a display form that reflects the items that are indicators for selecting the candidate tests. Thus, the user can select candidate tests taking into consideration the items that he or she considers important.

[0128] In addition, by accepting the specification of at least one additional item serving as an index for selecting the test candidates and updating the display form of the icon representing the test candidates according to the additionally specified item, the test candidates can be presented to the user in a display form that takes into consideration multiple items serving as indexes for selecting the test candidates, thereby enabling the user to easily select the test candidates.

[0129] Furthermore, by presenting the user with statistical information on previously selected test candidates, the user can more easily select a test method that is suitable for him or her.

[0130] In addition, by storing blood glucose equivalent values, abnormality trends, selected test candidates, meal images, etc. in the test server 6, the stored information can be used as big data. The stored big data can be used for learning AI that provides information related to blood glucose levels, or can be used as statistical information.

[0131] In the first embodiment, a test method that cannot be performed by the test device 1 may be presented as a test candidate. For example, a test method in which the user periodically draws his / her own blood or a test method in which blood is drawn at a hospital may be presented as a test candidate. In the case where such a test method is presented as a test candidate, for example, if the user selects a test method of self-drawing blood glucose level measurement at home because he / she wants to check his / her blood glucose level periodically in the future, the presentation unit 54 guides the user to a website that sells blood glucose meters (SMBG: Self Monitoring of Blood Glucose). FIG. 27 is a diagram showing a guide screen of a website that sells blood glucose meters. As shown in FIG. 27, a guide screen 93 displays a plurality of websites where blood glucose meters can be purchased. The user can purchase a blood glucose meter by accessing the displayed website.

[0132] On the other hand, when a test method performed at a hospital is presented as a test candidate, if the user has an intention to grasp the current state of his / her blood glucose level firmly and selects a glucose tolerance test at a hospital, the presentation unit 54 guides the user to hospitals that can perform a glucose tolerance test near the user's home or workplace. FIG. 28 is a diagram showing a guide screen that guides the user to hospitals that can perform a glucose tolerance test. As shown in FIG. 28, the guide screen 94 displays hospitals that can perform a glucose tolerance test near the user's workplace. In addition, the presented hospital names are selectable, and when a hospital name is selected, a list 95 of dates and times at which a glucose tolerance test can be reserved is displayed. FIG. 28 shows a state in which Hospital A is selected and a list of dates and times at Hospital A that can be reserved is displayed. The user can select a date and time marked with "○" and select a reservation button 96 to make a reservation for a glucose tolerance test at the selected hospital.

[0133] In the first embodiment, guidance is given at the time when the user selects a test from the test candidates and the process is terminated. However, a test candidate that is a step up from the test selected by the user may be proposed. For example, as shown in FIG. 12, in a case where six test candidates for a large postprandial hyperglycemic spike are presented, after the user selects one of the test candidates, guidance may be given to a test at a hospital as the next test candidate. FIG. 29 is a diagram showing a guidance screen for the next test. As shown in FIG. 29, the guidance screen 97 presents two test methods as the next step test, namely, a GA test and a 1,5AG test at a hospital, and a glucose tolerance test at a hospital. The user can recognize that it is preferable to perform a GA test and a 1,5AG test at a hospital, or a glucose tolerance test at a hospital next, by referring to the guidance screen 97.

[0134] The GA test is a test for glycoalbumin, and the 1,5AG test is a test for 1,5-anhydro-D-glucitol. Glucoalbumin is a combination of albumin, a type of protein in serum, and glucose, and is bioinformation that can tell you the state of your blood sugar levels from 1 to 2 weeks ago. 1,5AG is a type of sugar in the blood, and is the second most abundant sugar after glucose. By measuring 1,5AG as bioinformation, you can find out the state of your blood sugar levels over the past few days. A glucose tolerance test is a test that measures blood sugar levels by taking blood samples three times after a glucose load.

[0135] In the first embodiment, for example, due to a lack of measured values ​​of the blood glucose equivalent value, it may not be possible to determine whether the blood glucose level is on an abnormal trend. For example, the time the user wears the meter 3 is short, and the blood glucose equivalent value may not be monitored to the extent that a postprandial hyperglycemic spike can be determined. In such a case, the judgment unit 52 cannot judge whether the blood glucose level is on an abnormal trend. For this reason, when the judgment unit 52 cannot judge whether the blood glucose level is on an abnormal trend, it is preferable to issue a notification to encourage the user to increase the wearing time of the meter 3. FIG. 30 is a diagram showing a notification screen. As shown in FIG. 30, the notification screen 98 displays a notification 99 saying "Please increase the wearing time of the meter." The user can take an action to increase the wearing time of the meter 3 by the notification screen 98, and this makes it possible to judge whether the blood glucose equivalent value thereafter is on an abnormal trend.

[0136] In the first embodiment, the user may take a picture of the meal contents using the camera 28 of the mobile terminal 2 and transmit the image of the meal contents to the inspection device 1 together with the monitoring result of the blood glucose equivalent value. In this case, in the inspection device 1, if the meal contents are within two hours after the meal, the meal contents may be judged based on the image of the meal contents and the test candidates may be determined according to the meal contents. For example, if the abnormal tendency judged by the judgment unit 52 is a small postprandial hyperglycemic spike, and the judgement result of the meal contents shows that the meal contents have a low sugar content, it is considered that the postprandial hyperglycemic spike is small due to the influence of the meal. Therefore, the abnormal tendency of the blood glucose equivalent value may be changed to a large postprandial hyperglycemic spike, and the inspection methods (1) to (3) may be determined as the test candidates.

[0137] In the first embodiment, the candidate tests are presented to the user in a display format using a scale each time an item serving as an index for selecting the candidate tests is selected on the item list screen 70, but this is not limited to the above. A plurality of items may be selected at once on the item list screen 70. In this case, the display positions of the candidate tests on the scale for each of the selected items are determined, and the candidate tests are presented to the user in a display format in which icons of the candidate tests are displayed at the determined display positions.

[0138] In the first embodiment, when the item selection button 65 is selected, the item list screen 70 is displayed to allow the user to select an item that will be an index for selecting a candidate test, but this is not limited to the above. Before the testing device according to this embodiment determines an abnormal tendency based on the monitoring results of the blood glucose equivalent value, the user may be allowed to select an item that will be an index for selecting a candidate test in advance. Alternatively, the measuring device 3 may transmit an item that will be an index for selecting a candidate test to the testing device 1. In this case, a button instead of the item selection button 65 is displayed on the candidate test presentation screen 62, and by selecting this button, the candidate tests are presented to the user in the display form shown in FIG. 21, FIG. 22, or FIG. 24.

[0139] In addition, when the user is asked to select items that serve as indicators for selecting candidate tests in advance, the user may select items that include risk checks for various diseases. In such a case, the determination unit 53 may determine a test method that includes other multiple item tests as the candidate tests. For example, the test methods (2) and (3) shown in FIG. 8 may be determined as the candidate tests.

[0140] In the first embodiment, when an item that is an index for selecting a candidate test is selected on the item list screen 70, the user is asked a question, and the display position of the candidate test on the scale is determined according to the answer to the question, but this is not limited to the above. The display position of the candidate test on the scale may be determined according to the degree of desirability of the selected item without asking a question. For example, when the user selects the accuracy of the test, the display position is determined so that the icon of the candidate test with a higher accuracy is displayed at a higher accuracy position on the scale representing the accuracy of the test.

[0141] In the first embodiment, when the blood glucose equivalent value is not showing an abnormal trend, the notification "The blood glucose equivalent value is not showing an abnormal trend. Please continue with the current lifestyle habits" is given as shown in Fig. 11, but the content of the notification is not limited to this. When the blood glucose equivalent value is not showing an abnormal trend but shows a tendency for the blood glucose equivalent value to rise, it is preferable to give a notification including advice to be careful about lifestyle habits.

[0142] In the first embodiment, the blood glucose equivalent value is measured by the measuring devices 3 and 4, but the present invention is not limited to this. Instead of measuring the blood glucose equivalent value by the measuring devices 3 and 4, a urine sugar test may be performed to measure the urine sugar. In this case, the measured urine sugar value is an example of the first biological information. In the case of a urine sugar test, a urine sugar value can be obtained by using a urine sugar testing device, and this can be used as the blood glucose equivalent value. The urine sugar testing device is an example of a measuring device. In this case, the urine sugar testing device is provided with a communication function with the portable terminal 2, the measured urine sugar value is transmitted to the portable terminal 2, and the blood glucose equivalent value is monitored by the portable terminal 2 based on the urine sugar value.

[0143] On the other hand, when a urine sugar test is performed using test paper, the color of the test paper changes depending on the urine sugar. In this case, the test paper is photographed by the camera 28 of the mobile terminal 2 to obtain an image of the test paper, and the mobile terminal 2 can store the urine sugar value by recognizing the color of the test paper from the image of the test paper, and the stored urine sugar value can be transmitted from the mobile terminal 2 to the testing device 1 as the monitoring result of the blood glucose equivalent value. In this case, a measuring device is not required, so the user does not need to prepare the measuring devices 3, 4 or a urine sugar testing device. In this case, an abnormal tendency of the blood glucose equivalent value may be determined from the urine sugar value obtained by the mobile terminal 2.

[0144] Alternatively, the blood glucose equivalent value may be monitored by using an AGP (Ambulatory Glucose Profile) instead of the blood glucose equivalent value measured by the measuring device 3 or 4. The AGP is a useful analysis method for reading the tendency of blood glucose fluctuation, i.e., blood glucose trend, from the blood glucose value or the glucose value in the interstitial fluid obtained by continuous measurement for several days (https: / / dm-net.co.jp / trend / agp / 001.php). The AGP makes it easy to grasp the time periods in a day when hypoglycemia and hyperglycemia are likely to occur, as well as the time periods when blood glucose values ​​fluctuate greatly. Therefore, by monitoring the blood glucose equivalent value using the AGP, it is easy to determine the tendency of abnormal blood glucose equivalent values.

[0145] In the first embodiment, the blood glucose equivalent value measured by the measuring devices 3 and 4 may be monitored, and the results of the monitoring of the blood glucose equivalent value and the results of the test performed by the user by drawing blood may be presented to the user. FIG. 31 is a diagram showing the results of the comparison between the monitoring of the blood glucose equivalent value and the results of the test performed by the user by drawing blood. In FIG. 31, the solid line shows the monitoring result of the blood glucose equivalent value, and the dashed line shows the results of the test performed by drawing blood. As shown in FIG. 31, the blood glucose equivalent value measured by the measuring devices 3 and 4 tends to be higher than the actual blood glucose value. As shown in FIG. 31, by presenting the results of the comparison between the monitoring of the blood glucose equivalent value and the results of the test performed by the user by drawing blood to the user, the user can determine the deviation between the current blood glucose equivalent value and the actual blood glucose value.

[0146] In the first embodiment, when the test method (3) is selected, the user delivers the collected blood to the test center. When the test method (1), (2), or (4) is selected, the user may wish to have the collected blood delivered to the test center for testing. In this case, the presentation unit 54 of the test device 1 displays a guide screen for carrying out the delivery procedure on the touch panel 14. FIG. 32 is a diagram showing a guide screen for carrying out the delivery procedure for the test results. As shown in FIG. 32, the guide screen 100 displays boxes for inputting the user's name, address, telephone number, and email address. The user inputs the necessary information and selects the decision button 101. As a result, the destination of the sample is emailed to the user's email address. The user delivers the sample to the emailed destination. The test results will be delivered to the user at a later date. On the other hand, the test results can also be confirmed on the test device 1. In this case, the test results are transmitted from the test center to the test device 1, and the user can display the test results on the test device 1 by inputting his or her own ID or the like on the test device 1.

[0147] Note that the user performs user registration in order to use the inspection device 1. When the user information such as the name, address, and telephone number is notified to the inspection center for user registration, the inspection device 1 may access the inspection server 6 to acquire the user information, and display on the touch panel 14 a guide for confirming the user's name, address, telephone number, etc. based on the acquired user information.

[0148] Furthermore, when delivering a sample, a storage box for storing the sample may be provided in the testing device 1, the sample may be stored in the storage box, and the sample may be collected from the storage box at a set time and delivered to a testing center.

[0149] In the first embodiment, the postprandial hyperglycemic spike is determined as an abnormal tendency of the blood glucose equivalent value, but the present invention is not limited thereto. Fasting hyperglycemia, hypoglycemia, nocturnal hyperglycemia, etc. may be determined as an abnormal tendency determined by monitoring the blood glucose equivalent value. For example, in the case of hypoglycemia, the test candidates presented include a 5-hour loading test, a salivary cortisol test, a salivary cortisol + DHEA test, a delayed food allergy test, and an organic aciduria measurement. The 5-hour loading test is an almost essential test for hypoglycemia. The salivary cortisol test is a test to determine whether or not the subject is in a fatigued state due to stress. The DHEA test is a test for dehydroepiandrosterone sulfate. Dehydroepiandrosterone sulfate is a type of male hormone. The delayed food allergy test is a test to determine the severity of intestinal disorders. The organic aciduria measurement is a test to determine whether or not fungi are growing in the intestinal tract and releasing toxins.

[0150] [Second embodiment] In the above first embodiment, a form in which guidance corresponding to test candidates for acquiring biometric information related to blood glucose equivalent values ​​according to abnormal trends in blood glucose equivalent values ​​is presented to a user has been described, but the present disclosure is not limited thereto. For example, the technology of the present disclosure may be applied to a form in which guidance corresponding to test candidates for acquiring biometric information required for diagnosing various diseases such as infectious diseases and cancer is presented to a user. It is known that some of the various diseases show abnormal trends in physiological information such as heart rate, blood pressure, respiration, electrocardiogram, maximum oxygen intake, arterial blood oxygen saturation, and body temperature when the user is infected with the disease. In particular, if the technology of this embodiment can determine abnormal trends in various physiological information before the user becomes aware of the symptoms of the disease, and recommend the user to undergo various tests when there is an abnormal trend, this can contribute to early detection of diseases.

[0151] Below, an example of applying the novel coronavirus disease (COVID-19) as a specific example of such a disease will be described. In this embodiment, instead of the blood glucose equivalent value in the first embodiment, heart rate is applied as the first biological information. The heart rate is acquired by a sensor provided in the measuring device 3. Also, instead of the glucose, urinary sugar, blood glucose level, HbA1c, glycoalbumin, and 1,5AG in the first embodiment, a test result regarding the presence or absence of infection with the novel coronavirus is applied as the second biological information. In this embodiment, some overlapping explanations of the configuration and operation similar to those of the first embodiment will be omitted.

[0152] FIG. 33 is a schematic diagram showing an example of the transition of the heart rate variability (HRV), the amount of virus in the body, the amount of antibodies in the body, and the amount of virus excretion in a patient infected with the novel coronavirus infection. In FIG. 33, the heart rate variability is shown by a thick solid line, the amount of virus in the body by a thin solid line, the amount of antibodies in the body by a dashed line, and the amount of virus excretion by a dashed line. The horizontal axis of FIG. 33 indicates the day onset of symptoms such as fever and cough as day 0, and indicates the days after onset as positive and the days before onset as negative. Heart rate variability is a value that represents the variation of the time interval (RRI: RR Interval) of each heartbeat. Specifically, heart rate variability is represented by the standard deviation of the RRI (SDNN: Standard Deviation of the RR interval) in a predetermined period and / or the square root of the average of the squares of the differences between two consecutive RRIs (rMSSD: root Mean Square of Successive RR interval Differences), etc.

[0153] As shown in Figure 33, in the case of COVID-19, the amount of virus in the body begins to increase rapidly about 5 days before the onset of symptoms, and an abnormal tendency is observed in which the heart rate variability decreases accordingly. This is because, while non-infected individuals have fluctuations in which the heart rate increases during exercise and when under stress, and decreases when relaxed, infected individuals have poor heart rate tracking, resulting in a smaller degree of increase and decrease in heart rate. Thereafter, the amount of virus in the body reaches a maximum and the heart rate variability reaches a minimum around the onset of symptoms, and about 10 days after the onset of symptoms, the amount of antibodies in the body increases and the amount of virus in the body begins to decrease, and the heart rate variability gradually returns to normal.

[0154] In tests related to coronavirus disease, nasal swabs, saliva, and blood are used as specimens that can be self - collected by users (details will be described later). Therefore, the analysis device 18 in the present embodiment derives test results regarding the presence or absence of coronavirus infection as the second biological information by analyzing the user's nasal swabs, saliva, and blood. For this purpose, the analysis device 18 has a mechanism for collecting the user's nasal swabs, saliva, and blood and a mechanism for obtaining nasal swabs, saliva, and blood from the test kit 20A described later, etc.

[0155] The storage case 20 in the present embodiment houses a plurality of test kits 20A for collecting the user's nasal swabs, saliva, and blood respectively. The test kit 20A includes, for example, a cotton swab for collecting nasal swabs, a container for collecting saliva, and a blood sampling instrument.

[0156] The acquisition unit 51 acquires the heart - rate monitoring result transmitted from the communication I / F 35 of the measuring device 3 by receiving it through the communication I / F 15. In the present embodiment, for example, the heart - rate monitoring result measured in the most recent 24 hours is acquired.

[0157] The determination unit 52 determines whether the heart rate has an abnormal tendency based on the heart - rate monitoring result acquired by the acquisition unit 51. Specifically, the determination unit 52 calculates the heart - rate variation from the heart - rate monitoring result transmitted from the measuring device 3, and determines that the heart rate has an abnormal tendency when there is a situation where the heart - rate variation is equal to or less than a predetermined threshold Th11. In addition, the determination unit 52 determines that the degree of the abnormal tendency of the heart rate is large when the heart - rate variation is equal to or less than a threshold Th12 (where Th12 < Th11), and determines that the degree of the abnormal tendency of the heart rate is small when the heart - rate variation is less than Th11 and exceeds Th12.

[0158] The determination unit 52 may also determine whether the heart rate is abnormal by using representative values ​​such as the average and median of the heart rate fluctuation per unit time in a predetermined period (for example, the most recent 24 hours). This is because it is preferable not to regard a temporary increase in the heart rate fluctuation during exercise or in a state of tension as an abnormal tendency.

[0159] Furthermore, when there is a situation in which the heart rate variability is increasing (greater than or equal to the threshold value Th11), the determination unit 52 may determine whether the increase is temporary due to exercise, tension, or the like, and if it is determined that the increase is temporary, may exclude the period of increase and determine whether the heart rate is showing an abnormal tendency. The determination of whether the heart rate variability is a temporary increase may be performed by comparing with a temporary increase tendency of the heart rate variability in a similar situation in the past. Specifically, for example, a temporary increase pattern of the heart rate variability may be stored in the storage 13 in advance, and the determination unit 52 may determine whether the heart rate variability is a temporary increase by comparing the stored increase pattern with the monitoring result of the heart rate.

[0160] The deciding unit 53 decides candidate examinations to be recommended to the user when the judging unit 52 judges that the heart rate has an abnormal tendency.

[0161] A specific example of a method of determining test candidates by the determining unit 53 will be described with reference to FIG. 34. FIG. 34 is a table showing test methods related to COVID-19. In FIG. 34, for six types of test methods (C1) to (C6), the sample type, acquired biological information, cost, and required time are shown as test information. The table shown in FIG. 34 is stored, for example, as a table in the storage 13. Note that the contents of FIG. 34 are an example, and the test information, evaluations and conditions for each item may be updated as appropriate depending on the spread of COVID-19, the treatment status, and the progress of test methods, etc.

[0162] The test methods (C1) to (C2) are PCR (Polymerase Chain Reaction) tests using nasal swabs and saliva as the specimens, respectively. The test methods (C3) to (C4) are antigen quantitative tests using nasal swabs and saliva as the specimens, respectively. The test method (C5) is an antigen qualitative test using nasal swabs as the specimens. The test methods (C1) to (C5) can acquire test results on whether the subject is currently infected with COVID-19 as the second biological information. The test method (C6) is an antibody test using blood as the specimen, and can acquire test results on whether the subject has been infected with COVID-19 in the past as the second biological information. The determination unit 53 selectively determines test candidates from among a plurality of test methods (C1) to (C6) that include designation of the type of specimen and are used to acquire second biological information from the specimen.

[0163] Also, Fig. 34 shows various items that serve as indicators when the user selects the presented test candidates. The definitions and evaluation methods of the various items are the same as those in the first embodiment, so the explanation is omitted. However, regarding accuracy, the higher the degree to which a positive person can be detected as positive (so-called sensitivity), the higher the degree of desirability.

[0164] FIG. 34 also shows various conditions that the determination unit 53 uses to determine test candidates. Specifically, the conditions include the period during which testing is possible, and the suitability of testing for those with a small tendency to be abnormal, asymptomatic individuals, and high-risk individuals. The "period during which testing is possible" indicates a period during which the degree of detection of a positive case (so-called sensitivity) is relatively high and the test result is reliable. The "person with a small tendency to be abnormal" is a person who is determined by the determination unit 52 to have a small degree of tendency to be abnormal. The "asymptomatic individual" means a person who does not develop symptoms such as fever and cough. For those with a small tendency to be abnormal and asymptomatic individuals, a test method with a high sensitivity should be adopted to prevent overlooking due to false negatives, so that a test method with a relatively low sensitivity is not allowed. The "high-risk individual" is an individual who has risk factors such as aggravation and high difficulty of treatment, such as the elderly, individuals with underlying diseases, and pregnant women. For high-risk individuals, a test method with a relatively low sensitivity is not allowed because it is considered that a test should be performed more accurately to provide appropriate treatment quickly.

[0165] The determination unit 53 refers to the table in FIG. 34 and determines, as a test candidate, a test method suitable for various conditions from among the test methods (C1) to (C6). As shown in FIG. 34, in the case of COVID-19, the test possible period is determined based on the onset date. First, the determination unit 53 estimates the onset date based on the heart rate variability, and determines the test candidate depending on whether the current time is included in the test possible period based on the estimated onset date. For example, when it is estimated that the current time is two days before the onset date, the determination unit 53 determines the test methods (C1) to (C3) as the test candidates. Also, for example, when it is estimated that the current time is four days after the onset date, the determination unit 53 determines the test methods (C1) to (C5) as the test candidates. Also, for example, when it is estimated that the current time is 15 days or more after the onset date, the determination unit 53 determines the test method (C6) as the test candidate.

[0166] As a method for estimating the onset date, for example, based on the fact that there is a time lag of about 5 days from when the heart rate variability starts to show an abnormal tendency to the onset (see FIG. 33), the onset date may be estimated to be about 5 days after the determination unit 52 determines that the heart rate is abnormal. Also, for example, a learning model may be used that is trained using a pair of transition data of the heart rate variability of a patient infected with COVID-19 and the actual onset date as learning data, and that uses the transition data of the heart rate variability as input and an estimated onset date as output.

[0167] Secondly, the determination unit 53 determines the candidate tests according to the degree of the abnormal tendency of the heartbeat determined by the determination unit 52. For example, when the determination unit 52 determines that the abnormal tendency is small, the determination unit 53 determines the test methods (C2), (C4) and (C6) as the candidate tests. The determination unit 53 also determines the candidate tests in the same manner when the user is asymptomatic. On the other hand, when the determination unit 52 determines that the abnormal tendency is large, the determination unit 53 determines the test methods (C1) to (C6) as the candidate tests.

[0168] Third, the determination unit 53 determines the test candidates according to the risk factors possessed by the user. For example, if the user is a high-risk individual, the determination unit 53 determines the test methods (C1) to (C4) and (C6) as the test candidates. On the other hand, if the user is not a high-risk individual, the determination unit 53 determines the test methods (C1) to (C6) as the test candidates.

[0169] According to the above first to third determinations, the determination unit 53 determines the final test candidates. For example, if the current time is four days after the onset date, the determination unit 52 determines that there is a high tendency to abnormality, and the user is symptomatic and not a high-risk individual, the determination unit 53 determines the test methods (C1) to (C5) as the test candidates. Also, for example, if the current time is four days after the onset date, the determination unit 52 determines that there is a high tendency to abnormality, and the user is asymptomatic and not a high-risk individual, the determination unit 53 determines the test methods (C2) and (C4) as the test candidates.

[0170] The presentation unit 54 presents the candidate tests determined by the determination unit 53 to the user. Figs. 35 and 36 are diagrams showing an example of a presentation screen on which candidate tests are presented to the user in a display form in which icons of the candidate tests are displayed on a scale when two items, "cost" and "accuracy", are selected by the user. A scale 88 representing accuracy is displayed perpendicularly to a scale 87 representing cost on a presentation screen 86X in Figs. 35 and 36, and icons 801 to 805 of the candidate tests are displayed in a two-dimensional arrangement according to cost and accuracy. The icons 801 to 805 correspond to the test methods (C1) to (C5), respectively.

[0171] Fig. 35 shows a display screen in a case where the current time is four days after the onset date, the determination unit 52 has determined that there is a high tendency to be abnormal, and the user is symptomatic and not a high-risk individual. Fig. 36 shows a display screen in a case where the current time is four days after the onset date, the determination unit 52 has determined that there is a high tendency to be abnormal, and the user is asymptomatic and a high-risk individual. The display screen 86X allows the user to recognize at a glance the cost and accuracy of the presented candidate tests. This makes it easy to compare candidate tests taking into account both cost and accuracy.

[0172] The presentation unit 54 accepts the user's selection of the presented test candidates. Then, using the touch panel 14, the user is presented with guidance corresponding to the selected test candidate. For example, the user is guided to take out the test kit 20A for self-collection of one of nasal swabs, saliva, and blood from the storage case 20 according to the selected test candidate. The presentation unit 54 also presents the user with guidance on the method of self-collection. Information regarding these guidance may be stored in the storage 13. The presentation unit 54 may read out guidance corresponding to the test candidate selected by the user from the storage 13 and display the read out guidance on the touch panel 14. The user follows the guidance to self-collect one of nasal swabs, saliva, and blood.

[0173] The presenting unit 54 may present, as a guide, support information that supports the implementation of the selected test candidate, and that is transmitted from a remote location in real time. Furthermore, the test device 1 may be equipped with a camera that captures the user, and the presenting unit 54 may transmit to the remote location a video image obtained by capturing with the camera the user performing the selected test candidate. Specifically, a computer owned by a medical professional may be connected to the test device 1 via a network, so that the medical professional in a remote location may be able to guide the user on the self-collection method in real time. In this case, the camera equipped in the test device 1 may capture the user self-collecting nasal swab, saliva, and blood, and transmit the captured image to the computer of the medical professional in a remote location. The test device 1 may also be equipped with a speaker, and may play back audio guidance from the medical professional.

[0174] In addition, when the determination unit 53 determines that none of the test methods are suitable, for example, when the current time is three days or earlier than the onset date, the presentation unit 54 may present a guide to that effect. For example, the guide may be, "Your heart rate is showing an abnormal tendency, but a test will not provide accurate results at this time. Continue monitoring your heart rate." In addition, when the determination unit 52 determines that the heart rate is not showing an abnormal tendency, the presentation unit 54 may present a guide to that effect. For example, the guide may be, "Your heart rate is not showing an abnormal tendency at present. Continue taking measures against infection."

[0175] In this manner, in this embodiment, when the monitoring result of the user's heart rate shows an abnormal tendency, test candidates for obtaining test results related to the presence or absence of COVID-19 infection related to the heart rate are presented to the user, and guidance according to the test candidate selected by the user is presented to the user. Therefore, the user can use the testing device according to this embodiment to perform a test according to the monitoring result of the heart rate. In particular, in the case of COVID-19, the amount of virus discharged from an infected person, i.e., the infectivity to others, peaks around the onset date (see FIG. 33), so by determining the abnormal tendency of the heart rate before the onset date and suggesting the user to undergo a test, it is possible to contribute to preventing the spread of infection.

[0176] In the above second embodiment, the determination unit 52 determines whether the heart rate is abnormal based on the heart rate variability, but the present invention is not limited to this. The determination unit 52 may determine that the heart rate is abnormal when the value of the heart rate is equal to or greater than a predetermined threshold value for a predetermined period (e.g., three days) instead of the heart rate variability. This embodiment can contribute to early detection of diseases that cause the heart rate to remain high when the patient is ill. The determination unit 52 may determine that the heart rate is abnormal when the time variation of the heart rate (the difference between the maximum and minimum values ​​of the heart rate in a predetermined period (e.g., three days)) is equal to or greater than a predetermined threshold value instead of the heart rate variability. This embodiment can contribute to early detection of diseases that cause the heart rate to rise sharply when the patient is ill.

[0177] In the above-mentioned second embodiment, the heart rate is used as the first biological information, but the present invention is not limited to this. In the second embodiment, at least one of physiological information such as heart rate, blood pressure, respiration, electrocardiogram, maximum oxygen intake, arterial blood oxygen saturation, and body temperature may be used as the first biological information. These physiological information are acquired by a sensor provided in a wearable terminal such as a smart watch.

[0178] In the second embodiment, the second biometric information is applied to the test results regarding the presence or absence of infection with the new coronavirus, but the present invention is not limited to this. In the second embodiment, the second biometric information related to physiological information may be applied to the diagnosis results of the user's illness. Examples of the "disease diagnosis results" include the analysis results of components of the user's blood, urine, stool, nasopharyngeal swabs, nasal swabs, saliva, and other bodily fluids as specimens, and the detection results of pathogens such as viruses and bacteria. In addition, examples of the results of reading images taken by methods such as computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound, using the user's organs as specimens, such as the stomach, large intestine, lungs, uterus, and breasts, may be applied.

[0179] In the second embodiment, the diagnosis results of a plurality of different types of diseases may be applied as the second biological information related to the physiological information. For example, a test related to the novel coronavirus infection and a test related to influenza virus infection may both be presented as test candidates. Also, a guide to simultaneously undergo tests related to such a plurality of different types of diseases may be presented. In these cases, since diagnoses for various diseases can be recommended, it is possible to contribute to early detection of diseases.

[0180] In the second embodiment, the onset date and information on whether the user is an asymptomatic or high-risk person may be input by the user via the touch panel 14, for example. FIG. 37 is a diagram showing a question presentation screen for inputting these. As shown in FIG. 37, four questions Q1 to Q4 are displayed on the question presentation screen 75X. The user answers the questions Q1 to Q4 with YES or NO. If the question Q1 is YES, the determination unit 53 specifies the onset date by having the user input the onset date in the input box 76X. If the question Q1 is NO, the determination unit 53 specifies that the user is asymptomatic. If at least one of the questions Q2 to Q4 is YES, the determination unit 53 specifies that the user is a high-risk person. When the user selects the answer end button 77 after answering, the determination unit 53 determines the test candidate according to the answer results of the four questions Q1 to Q4.

[0181] Furthermore, in the second embodiment, the determination unit 53 may estimate whether the user is asymptomatic based on the fact that there is a time lag of about five days between when the heart rate shows an abnormal tendency and when the user develops symptoms (see FIG. 33). For example, if the current time is the second day after the heart rate shows an abnormal tendency, the determination unit 53 may estimate that the user is asymptomatic and has not yet developed symptoms. Also, for example, the determination unit 53 may determine the presence or absence of fever by measuring body temperature with the measuring device 3, and estimate that the user is asymptomatic if there is no fever.

[0182] In the second embodiment, the determining unit 53 estimates the onset date in accordance with the fact that the period during which the novel coronavirus infection can be tested is determined based on the onset date, but the present invention is not limited to this. For example, when influenza virus infection is the test subject, the time from infection to onset is short, about 1 to 2 days, and the difference between the date on which the first biological information begins to show an abnormal tendency and the onset date is small, so there is little point in estimating the onset date. Also, for example, when various lifestyle-related diseases are the test subjects, it is difficult to clearly estimate the onset date. However, even for these diseases, the appropriate test method may differ depending on the elapsed time from when the first biological information began to show an abnormal tendency. Therefore, the determining unit 53 may determine the test candidate depending on the elapsed time from the time when the first biological information was determined to have an abnormal tendency to the current time.

[0183] In addition, in the above second embodiment, whether the user is a close contact may be applied as a condition for determining test candidates. In the case of close contact, the possibility of being positive is relatively high, so it is considered that a test method with high sensitivity should be adopted to prevent overlooking due to false negatives. Therefore, a test method with relatively low sensitivity may be prohibited. Whether the user is a close contact may be detected by, for example, a known new coronavirus contact confirmation app.

[0184] In the second embodiment, after the COVID-19 infection test is performed, the test device 1 may determine whether or not to continue monitoring the heartbeat by feeding back the test result. For example, if the COVID-19 test is performed because the determination unit 52 has determined that the heartbeat is abnormal, and the test result is negative, it may be determined that the heartbeat monitoring should be continued. In particular, if the user falls into any of the following categories: a person with a small tendency toward abnormality, an asymptomatic person, a high-risk person, and a close contact, there is a high risk of overlooking a false negative and a sudden change in condition, so it is preferable to determine that the heartbeat monitoring should be continued.

[0185] Specifically, the acquisition unit 51 acquires a test result regarding the presence or absence of infection with the novel coronavirus infection. The test result may be transmitted from the analysis device 18 to the acquisition unit 51, or may be input by the user via the touch panel 14. If the acquired test result is negative, the presentation unit 54 determines that the heartbeat monitoring should be continued, and presents a guide to that effect to the user. If the heartbeat monitoring continues, the determination unit 52 determines whether the abnormal tendency of the heartbeat has become more pronounced and whether the abnormal tendency of the heartbeat is continuing. If the determination unit 52 determines that the abnormal tendency of the heartbeat has become more pronounced or is continuing, the determination unit 53 again determines a test candidate to be recommended to the user.

[0186] In the second embodiment, the test methods (C1) to (C6) in Fig. 34 do not include PCR tests, antigen quantitative tests, and antigen qualitative tests using nasopharyngeal swabs as specimens, which are commonly used as test methods for COVID-19. This is because it is difficult to collect a nasopharyngeal swab by oneself. However, for example, by placing a medical professional near the test device 1 and having the medical professional collect the user's nasopharyngeal swab, it is possible to select PCR tests, antigen quantitative tests, and antigen qualitative tests using nasopharyngeal swabs as specimens as test candidates.

[0187] In addition, in the second embodiment, in any of the test methods (C1) to (C6) in FIG. 34, a user may be guided to deliver the sample collected by the test kit 20A to a test center, and the test of the sample may be performed at the test center. In this case, the presenting unit 54 may transmit the user's heartbeat data and the test candidates determined by the determining unit 53 to the test center. This embodiment can assist medical staff at the test center in determining whether the test method selected by the user is appropriate. In these cases, the test device 1 does not need to include the analysis device 18.

[0188] In addition, in each of the above-described embodiments, the presenting unit 54 presents the candidate tests to the user by displaying them on the touch panel 14, but the presenting unit 54 may present the candidate tests to the user by voice.

[0189] Furthermore, in each of the above embodiments, the testing device 1 may be provided with a mechanism for cleaning locations that the user may come into contact with, such as the touch panel 14, the housing of the testing device 1, and the periphery of the installation location of the testing device 1, every time the user finishes using the testing device 1. Examples of cleaning means include wiping with a cloth, spraying with a disinfectant, and irradiating with ultraviolet light. In this manner, even if the user collects nasal swabs, saliva, blood, or the like from the user himself / herself, these locations do not become unsanitary, and the spread of infectious diseases can be prevented.

[0190] In addition, in each of the above embodiments, the monitoring results of the first biological information measured by the measuring devices 3 and 4 are transmitted to the testing device 1, but this is not limited to this. The first biological information measured by the measuring devices 3 and 4 may be transmitted to the portable terminal 2, and the monitoring results of the first biological information may be transmitted from the portable terminal 2 to the testing device 1.

[0191] In addition, in each of the above embodiments, the measuring devices 3 and 4 transmit the monitoring results of the first biological information measured to the testing device 1, and the determining unit 52 determines whether the first biological information has an abnormal tendency based on the monitoring results of the first biological information, but this is not limited to the above. The measuring devices 3 and 4 may determine whether the first biological information has an abnormal tendency based on the monitoring results of the first biological information, and transmit the determination results to the testing device 1. In this case, the measurement program 32 performs the process of determining the abnormal tendency. In the testing device 1, the determining unit 53 determines the test candidates based on the received determination results, without the determination being made by the determining unit 52.

[0192] Also, the first biological information measured by the measuring devices 3 and 4 may be transmitted to the mobile terminal 2, and the mobile terminal 2 may determine whether the first biological information has an abnormal tendency based on the monitoring results of the first biological information, and the determination result may be transmitted from the mobile terminal 2 to the testing device 1. In this case, the analysis program 22 performs the process of determining the abnormal tendency. Also, in the testing device 1, the determination unit 53 may determine the test candidates based on the received determination result, without the determination unit 52 performing a determination.

[0193] In each of the above embodiments, the following various processors can be used as the hardware structure of the processing unit that executes various processes, such as the acquisition unit 51, the judgment unit 52, the decision unit 53, and the presentation unit 54. As described above, the above various processors include a CPU, which is a general-purpose processor that executes software (programs) and functions as various processing units, as well as a programmable logic device (PLD), which is a processor whose circuit configuration can be changed after manufacture, such as an FPGA (Field Programmable Gate Array), and a dedicated electric circuit, which is a processor having a circuit configuration designed specifically for executing specific processes, such as an ASIC (Application Specific Integrated Circuit).

[0194] A single processing unit may be configured with one of these various processors, or may be configured with a combination of two or more processors of the same or different types (e.g., a combination of multiple FPGAs or a combination of a CPU and an FPGA). Also, multiple processing units may be configured with a single processor.

[0195] As an example of configuring multiple processing units with one processor, first, there is a form in which one processor is configured with a combination of one or more CPUs and software, as typified by computers such as client and server, and this processor functions as multiple processing units. Second, there is a form in which a processor is used that realizes the functions of the entire system including multiple processing units with one IC (Integrated Circuit) chip, as typified by System On Chip (SoC), etc. In this way, the various processing units are configured using one or more of the above various processors as a hardware structure.

[0196] Furthermore, more specifically, the hardware structure of these various processors can be an electric circuit that combines circuit elements such as semiconductor elements. [Explanation of symbols]

[0197] 1. Inspection equipment 2. Mobile devices 3,4 Measuring instruments 4A filament 5. Network 6. Inspection Server 10. Inspection Support System 11,21,31 CPU 12 Inspection Program 13,23,33 Storage 14,24,34 Touch Panel 15, 25, 35, 43 Communication I / F 16,26,36,42 Memory 17,27,37 Network I / F 18 Analyzer 19, 29, 39 Bus 20 Confiscated Cases 22 Analysis Program 28 Camera 32 Measurement Program 41 Processors 44 Sensors 51 Acquisition Department 52 Judgment section 53 Decision Section 54 Presentation section 60 Notification screen 61 Notification 62,62A,62B,62C Presentation screen 63, 63A, 63B, 63C Test Candidates 64 Statistics button 65 Item selection button 66 Confirm button 67 Explanation 68 Statistics 69 Action Plan 70 List screen 71 Checkbox 72 Item specification button 75,75X,84 Question presentation screen 76,76X,90 Input box 77,85 Answer end button 78,78A,86,86X Presentation screen 79,87,88 scale 80A~80I,801~805 Test candidate icons 81 Confirm button 82 Item selection button 89,93,94,97 Guidance screen 91,96 Reservation button 92 Analysis result display screen 98 Notification screen 99 notifications 100 Shipping procedure information screen 101 Decision button

Claims

1. At least one processor; The processor, Obtaining a determination result as to whether or not the first biological information of the user is showing a tendency toward abnormality, the determination result being determined based on a plurality of measurement results of the first biological information of the user; When the determination result indicates the tendency toward abnormality, acquiring at least one candidate test for acquiring second biological information associated with the first biological information, the candidate test being recommended to the user; presenting the obtained test candidates to the user; Accepting a selection of the proposed test candidates; Present the user with guidance corresponding to the selected candidate examination. Inspection equipment.

2. At least one processor; The processor, Obtaining a determination result as to whether or not the first biological information of the user is showing a tendency toward abnormality, the determination result being determined based on a monitoring result of the first biological information of the user; If the determination result indicates the tendency toward abnormality, presenting to the user at least one test candidate for acquiring second biological information related to the first biological information; Present the user with guidance corresponding to the candidate examination selected by the user. Inspection equipment.

3. A candidate test for collecting a sample from the user to obtain the second biological information is presented by the processor, and when the candidate test is selected, the processor presents a guide for collecting the sample to the user; The second biological information based on the sample collected by the user is acquired.

3. The inspection device according to claim 1 or 2.

4. The processor presents the second biometric information to the user.

4. The inspection device according to claim 3.

5. The apparatus further includes an analysis device that derives the second biological information by analyzing the collected sample.

5. The inspection device according to claim 3 or 4.

6. A candidate test for delivering the user's sample to an external testing institution to obtain the second biometric information is presented by the processor, and when the candidate test is selected, the processor presents the user with a guide for a procedure for delivering the user's first biometric information to the user. The inspection device according to any one of claims 1 to 5.

7. The device further includes a storage case for storing a test kit necessary for carrying out a test according to the presented test candidates. The inspection device according to any one of claims 1 to 6.

8. The test candidates include test candidates that can obtain the second biometric information with higher accuracy than the first biometric information. The inspection device according to any one of claims 1 to 7.

9. The processor, Accepting designation of at least one item that serves as an indicator for a user to select the presented test candidates; The examination candidates are presented in a display format according to the designated items. The inspection device according to any one of claims 1 to 8.

10. The processor, presenting the user with a question for determining a display position of the candidate test on at least one scale according to the at least one specified item; determining a display position of the candidate test on the scale in response to the answer to the question; The candidate examinations are presented to the user in a display format in which an icon representing the candidate examination is displayed at the determined display position on the scale.

10. The inspection apparatus according to claim 9.

11. The processor, After displaying the icon representing the examination candidate, a designation of addition of the item by the user can be accepted; When the designation of the item is added, the display form of the icon representing the examination candidate is updated. The inspection apparatus according to claim 10.

12. The processor repeats accepting a designation of an additional item, presenting a question corresponding to the added item, and updating a display mode of the candidate test until a candidate test is selected by the user. The inspection apparatus according to claim 11.

13. The items include at least one of the following: the cost of the test, the sense of security when the specimen is collected, the degree of restraint during the test, whether the test is invasive or non-invasive, the time required to obtain the test results, whether risk checks for various diseases are included, and the accuracy of the test.

13. The inspection device according to claim 9.

14. The processor selectively determines the candidate test from among a plurality of test methods including a designation of a type of subject and for acquiring the second biological information from the subject.

14. An inspection device according to any one of claims 1 to 13.

15. The processor determines the test candidates according to the degree of the abnormal tendency.

15. An inspection device according to any one of claims 1 to 14.

16. The processor determines the test candidate according to an elapsed time from a time when the first biological information was determined to have the tendency toward abnormality to a current time.

16. An inspection device according to any one of claims 1 to 15.

17. The processor determines the test candidates according to risk factors possessed by the user.

17. An inspection device according to any one of claims 1 to 16.

18. The processor presents, as the guidance, support information for supporting the implementation of the selected test candidate, the support information being transmitted in real time from a remote location.

18. An inspection device according to any one of claims 1 to 17.

19. A camera for photographing the user is provided, The processor transmits to the remote location a video image obtained by capturing with the camera a state in which the user is performing the selected candidate examination.

20. The inspection apparatus of claim 18.

20. The processor presents statistical information of previously selected test candidates to the user.

20. An inspection device according to any one of claims 1 to 19.

21. the first biological information is a blood glucose equivalent value having a correlation with a blood glucose level, The second biological information includes at least one of a blood glucose level and HbA1c.

21. An inspection device according to any one of claims 1 to 20.

22. The abnormal tendency is a postprandial hyperglycemic spike.

22. An inspection device according to any one of claims 1 to 21.

23. The processor determines the test candidates based on the diet of the user.

23. The inspection apparatus of claim 22.

24. The processor determines the test candidates based on the mealtime of the user.

24. An inspection device according to claim 22 or 23.

25. The processor presents a test candidate including an act of drinking a glucose drink when a time elapsed since a meal based on the meal time has passed a predetermined time.

25. The inspection apparatus of claim 24.

26. the first biological information is at least one of a heart rate, a blood pressure, a respiration rate, an electrocardiogram, a maximum oxygen intake, an arterial blood oxygen saturation, and a body temperature; The second biological information is a diagnosis of a disease of the user.

21. An inspection device according to any one of claims 1 to 20.

27. When the processor obtains a determination result indicating that the first biological information does not tend to be abnormal, the processor notifies the user of the result.

27. An inspection apparatus according to any one of claims 1 to 26.

28. The processor obtains the determination result via wireless communication.

28. An inspection apparatus according to any one of claims 1 to 27.

29. the determination result is derived by a measuring device attached to the user; The processor acquires the determination result from the measuring device.

29. An inspection apparatus according to any one of claims 1 to 28.

30. the first biological information is measured a plurality of times by a measuring device attached to the user; The processor acquires a plurality of measurement results of the first biological information from the measurement device; Based on the results of a plurality of measurements of the first biological information obtained, it is determined whether the first biological information shows a tendency toward abnormality, and the determination result is obtained.

28. An inspection apparatus according to any one of claims 1 to 27.

31. The measuring device is wearable 31. An inspection device according to claim 29 or 30.

32. If it is not possible to determine whether the first biological information is showing an abnormal tendency, The processor issues a notification to increase the wearing time of the measuring device.

32. An inspection device according to any one of claims 29 to 31.

33. The processor, Acquiring the second biometric information; A determination is made as to whether or not the measurement of the first biological information should be continued according to the acquired second biological information.

33. An inspection apparatus according to any one of claims 1 to 32.

34. The processor, after presenting the user with guidance corresponding to the selected test candidate, further presents guidance corresponding to another test candidate that performs a step-up test compared to the selected test candidate.

34. An inspection apparatus according to any one of claims 1 to 33.

Images